Health Care & Life Sciences » Biotechnology | Momenta Pharmaceuticals Inc.

Momenta Pharmaceuticals Inc. | Ownership

Companies that own Momenta Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
11,524,493
14.72%
114,241
0.03%
06/30/2018
BlackRock Fund Advisors
11,034,851
14.09%
878,838
0.02%
06/30/2018
The Vanguard Group, Inc.
7,156,372
9.14%
292,800
0.01%
06/30/2018
Wellington Management Co. LLP
3,810,434
4.87%
-5,083,262
0.02%
06/30/2018
RA Capital Management LLC
3,702,533
4.73%
3,702,533
5.41%
06/30/2018
SSgA Funds Management, Inc.
3,438,794
4.38%
-102,852
0.01%
06/30/2018
Camber Capital Management LLC
3,055,000
3.9%
2,919,700
3.29%
06/30/2018
PRIMECAP Management Co.
2,888,100
3.69%
0
0.05%
06/30/2018
D. E. Shaw & Co. LP
2,244,309
2.87%
196,932
0.09%
06/30/2018
Henderson Global Investors Ltd.
2,208,986
2.82%
336,859
0.03%
06/30/2018

About Momenta Pharmaceuticals

View Profile
Address
301 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.momentapharma.com
Updated 07/08/2019
Momenta Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products. It focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune disease. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.